David S. Boyer, MD - An Eye Toward Improving Adherence: Easing the DME Treatment Burden With Longer-Acting Anti-VEGF Agents

episode

CME in Minutes: Education in Primary Care not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Full Show Podcast: 23 September 2026 1h 29m · 22 Sep 2026 · The Mike Hosking Breakfast

Evening Wire: Trump Delivers Remarks to the UN & Nolan Wells Drowning Updates | 9.22.26 11 min · 22 Sep 2026 · Morning Wire

Willie Robertson Wouldn’t Let His Kids Open Their Own Gifts | Duck Call Room #589 59 min · 22 Sep 2026 · Duck Call Room

🎙Tell us your Group Chat Names - The Chat 10 min · 22 Sep 2026 · The Hauraki Breakfast Podcast

MORNING TEA: Taylor Swift's Surprise New Single & William and Kate Hit The Red Carpet With Tom Cruise 7 min · 22 Sep 2026 · The Spill

Trump Touts Foreign Policy Vision in UN Speech Ahead of Midterms 13 min · 22 Sep 2026 · WSJ What’s News

Report any issue

Source

Recorded23 Aug 2023

Publisherc.answersincme.com ↗

Handlerec:10296349

Show notes

Please visit answersincme.com/YYB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses strategies for selecting anti-VEGF therapy and maintaining adherence for patients with diabetic macular edema. Upon completion of this activity, participants should be better able to: Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with diabetic macular edema (DME); Review the clinical profiles of longer-acting vascular endothelial growth factor (VEGF)-targeted agents with phase 3 trial evidence in the treatment of DME; and Outline patient-centered management approaches to improve adherence to VEGF-targeted therapy.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in